Singapore, Oct. 31 -- Australia-based Myrio Therapeutics has announced a collaborative research partnership with the University of Pennsylvania's Perelman School of Medicine and NYU Langone Health, in the US, to accelerate the development of next generation solid tumor T cell immunotherapeutics.

By combining their strengths, the three parties will generate deeper insights into these mechanisms and explore the therapeutic potential of these technologies.The next step will be to formally establish a company and initiate seed funding to move these advances toward clinical development.

"A major challenge in the development of cancer treatment is creating tolerable approaches that also deliver effective and long-lasting response in patients,...